Ligand Pharmaceuticals | LGND - Operating Profit


Ligand Pharmaceuticals reported $60.33M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.83B 130M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Baxter International USD 66M 280.2M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Enviri Corporation USD -35.28M 61.58M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 19.08M 5.55M Mar/2026